Approval · Notice of Compliance 3822 · 1997
LENTARON: Notice of Compliance 3822
Issued June 27, 1997
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3822
- Date
- June 27, 1997
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Therapeutic class
- Steroidal aromatase inhibitor; inhibitor of estrogen biosynthesis; antitumour agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LENTARON | 02128209 | Cancelled Post Market |
Medicinal ingredients
- FORMESTANE 250 MG per KIT